The S&P/ASX 200 index slipped 0.3 per cent to 6,974, closing lower for the second straight session. Last week, it had posted its best weekly performance in nine.
Over the weekend, Australia dropped its goal to inoculate nearly all of its population by the end of 2021 following advice that people under the age of 50 take Pfizer’s COVID-19 vaccine over AstraZeneca’s shot.
“The market is mainly down on (the) vaccination target cancellation debacle and the pop in bond yields,” said Mathan Somasundaram, Chief Executive Officer at Deep Data Analytics.
Trading turnover has been relatively low for last three weeks and this week also started with low turnover, Somasundaram said, adding that: “Any market volatility will be exaggerated in low turnover.”
Travel-related stocks were hit by setbacks in vaccination efforts. Ticket booking and tour operating firm Webjet and carrier Qantas Airways slipped more than 2 per cent each.
Miners tumbled 1.3 per cent to mark their second straight session of falls on subdued iron ore prices.
The country’s mining triumvirate – BHP Group, Rio Tinto and Fortescue – fell between 0.9 per cent and 2.2 per cent.
Gold stocks dropped 2.6 per cent, snapping a five-session winning run, as bullion prices sagged after data showing robust readings for U.S. inflation and a faster economic rebound bolstered Treasury yields.
Newcrest, the country’s biggest gold miner, skidded 2.6 per cent and Northern Star Resources fell 2.8 per cent.
Healthcare stocks outperformed the benchmark to close 0.7 per cent higher.
rose 0.9 per cent, while ResMed gained 1.8 per cent.
New Zealand’s benchmark S&P/NZX 50 index fell 0.4 per cent to close at 12,518.7, marking its second straight session of drop.
